Protein aggregation and misfolding represent central pathological mechanisms in neurodegenerative diseases, characterized by the accumulation of misfolded protein aggregates in the brain. These aggregates disrupt cellular function, propagate between cells, and ultimately lead to neuronal death. The failure of protein homeostasis (proteostasis) networks—including molecular chaperones, the ubiquitin-proteasome system, and autophagy—underlies the formation of these toxic species.[1] [1:1]
The prion-like propagation of misfolded proteins represents a unique pathological mechanism in which aggregated proteins can templat the misfolding of native proteins, leading to progressive spreading throughout the brain. This mechanism has been implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and frontotemporal dementia.[2] [2:1]
Amyloid-beta is a 38-43 amino acid peptide generated through proteolytic cleavage of the amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase. Aβ40 and Aβ42 are the major isoforms, with Aβ42 showing greater aggregation propensity due to its two additional hydrophobic residues at the C-terminus.[3] [3:1]
In Alzheimer's disease, Aβ aggregates form extracellular senile plaques, which are one of the hallmark pathological features. The amyloid cascade hypothesis posits that Aβ accumulation initiates a cascade of events including tau pathology, synaptic dysfunction, neuroinflammation, and neuronal loss.[4] [4:1]
Tau is a microtubule-associated protein that stabilizes axonal microtubules. In Alzheimer's disease and other tauopathies, tau becomes hyperphosphorylated, leading to its detachment from microtubules and aggregation into paired helical filaments (PHFs) and neurofibrillary tangles (NFTs).[5] [5:1]
Alpha-synuclein is a presynaptic protein that regulates synaptic vesicle trafficking. In Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, alpha-synuclein misfolds into beta-sheet rich oligomers and fibrils that form Lewy bodies and Lewy neurites.[6] [6:1]
TAR DNA-binding protein 43 (TDP-43) is a nuclear protein involved in RNA metabolism. In ALS and frontotemporal dementia, TDP-43 forms cytoplasmic inclusions that are the hallmark pathology in the majority of these cases.[7] [7:1]
Huntingtin is a large protein with an N-terminal polyglutamine (polyQ) tract. In Huntington's disease, expansion of this polyQ tract leads to mutant huntingtin protein that forms toxic aggregates in neurons.[8] [8:1]
Copper/zinc superoxide dismutase (SOD1) is normally a cytosolic enzyme that scavenges superoxide radicals. In familial ALS, over 150 mutations in SOD1 cause the protein to misfold and form toxic aggregates.[9] [9:1]
Protein aggregation typically follows a nucleated polymerization mechanism:
The prion-like propagation of protein aggregates involves:
The terms "seeding" and "templating" are often used interchangeably but represent distinct mechanisms in prion-like propagation:
Seeding refers to the initiation of aggregation through pre-formed aggregates that serve as nucleation centers. Seeds bypass the rate-limiting step of spontaneous nucleation by providing a surface for monomer addition. The seed's conformation dictates the architecture of the resulting aggregate, enabling strain-specific polymerization.
Templating (or template-directed misfolding) describes the process by which an existing aggregate induces a conformational change in a native protein, converting it to the same aggregated conformation. This is an active, stoichiometric process where the template catalyzes the conversion of multiple native monomers. The template remains intact and can continue to catalyze conversions, making this a highly efficient amplification mechanism.
Both processes contribute to prion-like propagation: seeds initiate new aggregate formation, while templating drives the exponential amplification of pathology through endogenous protein conversion.
Beyond primary nucleation, protein aggregates can propagate through secondary nucleation mechanisms:
Fragmentation: Mature fibrils can break into smaller pieces, generating new ends that serve as growth sites. This dramatically accelerates aggregation kinetics by increasing the number of active elongation sites. Fragmentation can be induced by mechanical stress, enzymatic activity (e.g., calpain cleavage), or cellular machinery.
Surface-catalyzed nucleation: Aggregate surfaces can catalyze the formation of new nuclei, independent of fragmentation. This secondary nucleation creates a positive feedback loop where more aggregate surface area leads to more nucleation events.
Daughter filament formation: From a single parent fibril, multiple daughter filaments can branch off, creating a network of interconnected aggregates that spread throughout tissue.
Misfolded protein aggregates cause toxicity through multiple mechanisms:
Molecular chaperones facilitate proper protein folding and prevent aggregation:
The UPS degrades misfolded proteins:
Autophagy degrades larger protein aggregates:
Multiple therapeutic approaches target protein aggregation:
Small Molecule Inhibitors: Compounds that prevent aggregation or promote clearance
Immunotherapy: Antibodies to clear aggregated proteins
Enhancing Proteostasis: Boosting cellular clearance mechanisms
Recent research has revealed that cellular membranes play a critical role in protein aggregation:
Phase separation has emerged as a key mechanism in protein aggregation:
The concept of prion-like strains has been refined:
Synaptic terminals are particularly vulnerable to protein aggregation:
Passive immunization approaches:
Active immunization:
| Compound | Target | Status | Company |
|---|---|---|---|
| Anle305b | Aβ oligomers | Preclinical | -- |
| Anle138b | α-synuclein oligomers | Phase 1 | -- |
| EGCG | Multiple aggregates | Phase 2 | -- |
| Curcumin | Aβ aggregation | Phase 2 | -- |
Emerging nanotechnology-based strategies:
Molecular chaperone systems represent endogenous defense mechanisms against protein aggregation, and enhancing these pathways shows therapeutic promise. Hsp70 inducers such as geranylgeranylacetone have been shown to reduce protein aggregate burden in cellular and animal models. Hsp90 inhibitors like geldanamycin derivatives promote clearance of mutant proteins by activating Hsp70-dependent quality control. Small molecule stabilizers that directly stabilize native protein conformation are under development, targeting the earliest steps in the aggregation pathway.
Autophagy enhancement addresses the fundamental problem of failed protein clearance. While mTOR inhibitors like rapamycin effectively induce autophagy, their immunosuppressive side effects limit clinical utility. mTOR-independent enhancers including trehalose, lithium, and carbamazepine activate autophagy through alternative pathways, providing safer alternatives. TFEB agonists that promote transcription of lysosomal biogenesis genes represent a promising approach, with several candidates in preclinical development.
Passive immunization using monoclonal antibodies has advanced significantly, with multiple candidates in clinical trials. Anti-tau antibodies including gosuranemab and zagotenemab target extracellular tau species and have shown biomarker evidence of target engagement. Anti-alpha-synuclein antibodies such as prasinezumab aim to clear spreading species before they template endogenous protein misfolding. Active immunization approaches using tau or alpha-synuclein peptide conjugates aim to generate endogenous antibody responses, potentially providing longer-lasting protection.
Emerging degradation technologies offer new strategies for aggregate removal. PROTACs (proteolysis-targeting chimeras) recruit E3 ubiquitin ligases to bring aggregating proteins into proximity with the proteasome. Molecular glues like thalidomide derivatives promote degradation of specific targets through induced proximity. AUTACs (autophagy-targeting chimeras) engage autophagy machinery for selective degradation of protein aggregates, addressing the limitation of proteasome-mediated clearance for large inclusions.
Protein aggregation overwhelms cellular qual
Accumulation of misfolded proteins in the ER lumen triggers the unf### MitochoProtein aggreg### Synaptic Dysfu
Synaptic terminals represent early casualties in protein aggregatio
Astrocytes and microglia respond to protein aggregates with inflammatory activation that can be protective or damaging.
Induced pluripotent stem cell (iPSC) derived neurons from p
Transgenic mouse models expressing mutant human proteins develop aggregate pathology that sh
Synthetic peptide and protein aggregation systems enable mechanistic studies with defined conditions. Thioflavin T fluorescence monitors fibril formation kinetics. Atomic force microscopy and cryo-EM visualize aggregate structures at high resolution. Single-molecule approaches reveal the stochastic nature of nucleation events and the heterogeneity of aggregate species.
Cerebrospinal fluid (CSF) levels of total tau, phosphorylated tau, and amyloid-beta provide established biomarkers for Alzheimer's disease. Neurofilament light chain (NfL) in CSF and blood marks neuronal injury across neurodegenerative conditions. Newer assays detect specific aggregation species including tau oligomers and alpha-synuclein aggregates, potentially enabling earlier diagnosis and disease staging.
PET tracers for amyloid (Pittsburgh B compound), tau (flortaucipir), and alpha-synuclein enable in vivo visualization of protein pathology. These imaging approaches allow tracking of disease progression and assessment of therapeutic responses. Advances in tau PET have enabled discrimination of 3R and 4R tauopathy subtypes.
Alpha-synuclein seeding amplification assays detect pathological species in CSF, blood, and tissue samples with high sensitivity. Skin biopsies reveal peripheral alpha-synuclein deposits. Gut microbiome alterations may serve as early indicators of Parkinson's disease risk.
Single-molecule imaging and spectroscopy reveal the heterogeneity of aggregate species and the stochastic nature of aggregation. These approaches distinguish toxic oligomers from mature fibrils and enable correlation of specific species with cellular dysfunction.
Proteomic and metabolomic approaches identify how aggregation affects cellular networks broadly. Systems biology integration of these data with computational models of aggregation kinetics may predict disease progression and therapeutic responses.
Deep learning models trained on cryo-EM structures predict aggregation-prone sequences and identify potential aggregation inhibitors. AI approaches also analyze medical imaging and clinical data to identify patients most likely to benefit from anti-aggregation therapies.
Soto C, et al. '"Protein misfolding, aggregation, and neurodegenerative diseases." Nat Rev Neurosci 2007;8:724-735'. 2007. ↩︎ ↩︎
Jucker M, Walker LC. "Propagation of protein aggregation in neurodegenerative diseases." Nature 2019;577:49-58. 2019. ↩︎ ↩︎
Oakley H, et al. '"The amyloid-beta peptide from Alzheimer disease brain." J Biol Chem 2006;281:32929-32936'. 2006. ↩︎ ↩︎
'Hardy J, Selkoe DJ. "The amyloid hypothesis of Alzheimer''s disease: progress and problems on the road to therapeutics." Science 2002;297:353-356'. 2002. ↩︎ ↩︎
Mandelkow E, Mandelkow E. "Tau in physiology and pathology." Nat Rev Neurosci 2012;13:51-62. 2012. ↩︎ ↩︎
Spillantini MG, et al. '"Alpha-synuclein in Lewy bodies." Nature 1997;388:839-840'. 1997. ↩︎ ↩︎
Neumann M, et al. '"Ubiquitinated TDP-43 in frontotemporal dementia and amyotrophic lateral sclerosis." Science 2006;314:130-133'. 2006. ↩︎ ↩︎
Scherzinger E, et al. [ '"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo." Cell 1997;90:549-558'](https://doi.org/10.1016/S0092-8674(00). 1997. ↩︎ ↩︎
Broom JD, et al. '"ALS mutations in SOD1: the emergence of a new paradigm." Brain Res 2016;1647:1-10'. 2016. ↩︎ ↩︎
Guo JL, et al. '"Prion-like propagation by alpha-synuclein." Cold Spring Harb Perspect Med 2018;8:a024398'. 2018. ↩︎ ↩︎
Mullally G, et al. '"Protein aggregation in neurodegeneration: beneficial strategies?" Nat Rev Neurol 2020;16:259-271'. 2020. ↩︎ ↩︎